Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has delayed the review of Regeneron Pharmaceuticals' Eylea biologics license application (BLA) to 18 November 2011.
Subscribe to our email newsletter
Eylea is indicated as a treatment for neovascular age-related macular degeneration (wet AMD).
The extension of three months follows the recent amendment made by the company on the chemistry, manufacturing and controls (CMC) section of the BLA.
The new action date will give the agency additional time to review the information submitted.